NasdaqGS - Nasdaq Real Time Price USD

Madrigal Pharmaceuticals, Inc. (MDGL)

Compare
319.58 +60.24 (+23.23%)
At close: 4:00 p.m. EDT
319.58 0.00 (0.00%)
After hours: 4:20 p.m. EDT
Advanced Chart
Loading Chart for MDGL
DELL
  • Previous Close 259.34
  • Open 268.38
  • Bid 318.58 x 100
  • Ask 346.29 x 200
  • Day's Range 265.01 - 321.19
  • 52 Week Range 133.99 - 321.19
  • Volume 2,925,820
  • Avg. Volume 293,450
  • Market Cap (intraday) 6.97B
  • Beta (5Y Monthly) -0.45
  • PE Ratio (TTM) --
  • EPS (TTM) -25.54
  • Earnings Date Oct 31, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 362.33

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

www.madrigalpharma.com

376

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Madrigal Pharmaceuticals, Inc.

Recent News: MDGL

View More
View More

Related Videos: MDGL

Madrigal Pharmaceuticals stock jumps on MASH drug hopes

Madrigal Pharmaceuticals (MDGL) shares jumped after Novo Nordisk (NVO) announced that a trial showed its weight-loss drug Wegovy helped those with a fatty liver disease called MASH. Madrigal has its own MASH treatment. Analysts think that the Wegovy news will do a couple of things. First it helps raise awareness of the disease. They also note Madrigal's treatment could address certain issues related to the disease that Wegovy can't. Market Domination Anchors Julie Hyman and Josh Lipton discuss the news in the video above.  To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Stephanie Mikulich.
Yahoo Finance Video · 11 mins ago
MDGL
+23.23%

Performance Overview: MDGL

Trailing total returns as of 2024-11-01, which may include dividends or other distributions. Benchmark is

.

YTD Return

MDGL
38.12%
S&P 500
20.10%

1-Year Return

MDGL
143.25%
S&P 500
36.60%

3-Year Return

MDGL
311.04%
S&P 500
24.39%

5-Year Return

MDGL
245.75%
S&P 500
88.60%

Compare To: MDGL

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

MDGL
Madrigal Pharmaceuticals, Inc.
319.58
+23.23%
Mkt Cap 6.97B
Industry Biotechnology
VKTX
Viking Therapeutics, Inc.
72.88
+0.47%
Mkt Cap 8.121B
Industry Biotechnology
IOVA
Iovance Biotherapeutics, Inc.
11.19
+7.18%
Mkt Cap 3.396B
Industry Biotechnology
TGTX
TG Therapeutics, Inc.
26.90
+7.34%
Mkt Cap 4.165B
Industry Biotechnology
AXSM
Axsome Therapeutics, Inc.
88.84
-0.21%
Mkt Cap 4.264B
Industry Biotechnology
DAWN
Day One Biopharmaceuticals, Inc.
14.65
-0.48%
Mkt Cap 1.477B
Industry Biotechnology
BPMC
Blueprint Medicines Corporation
90.70
+3.65%
Mkt Cap 5.762B
Industry Biotechnology
SMMT
Summit Therapeutics Inc.
18.99
+2.15%
Mkt Cap 14.004B
Industry Biotechnology
ARDX
Ardelyx, Inc.
6.09
+3.75%
Mkt Cap 1.434B
Industry Biotechnology
GLUE
Monte Rosa Therapeutics, Inc.
8.90
+4.71%
Mkt Cap 546.218M
Industry Biotechnology
INCY
Incyte Corporation
76.13
+2.71%
Mkt Cap 14.666B
Industry Biotechnology

Statistics: MDGL

View More

Valuation Measures

As of 2024-10-31

  • Market Cap

    5.66B

  • Enterprise Value

    4.72B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    352.81

  • Price/Book (mrq)

    6.60

  • Enterprise Value/Revenue

    320.48

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -47.27%

  • Return on Equity (ttm)

    -106.27%

  • Revenue (ttm)

    14.64M

  • Net Income Avi to Common (ttm)

    -510.45M

  • Diluted EPS (ttm)

    -25.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.06B

  • Total Debt/Equity (mrq)

    13.77%

  • Levered Free Cash Flow (ttm)

    -278.01M

View More

Research Analysis: MDGL

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 14.64M
Earnings -151.97M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

155.00 Low
362.33 Average
319.58 Current
511.00 High
 
View More

People Also Watch

VKTX Viking Therapeutics, Inc.
72.88
+0.47%
 
AKRO Akero Therapeutics, Inc.
32.33
+4.87%
 
APLS Apellis Pharmaceuticals, Inc.
27.98
+2.64%
 
BPMC Blueprint Medicines Corporation
90.70
+3.65%
 
AXSM Axsome Therapeutics, Inc.
88.84
-0.21%
 
KRYS Krystal Biotech, Inc.
176.39
+2.24%
 
SAGE Sage Therapeutics, Inc.
6.05
-0.49%
 
BBIO BridgeBio Pharma, Inc.
25.48
+8.84%
 
ARGX argenx SE
595.58
+1.58%
 
TGTX TG Therapeutics, Inc.
26.90
+7.34%
 
RGNX REGENXBIO Inc.
8.79
+2.33%
 
RYTM Rhythm Pharmaceuticals, Inc.
49.01
+2.68%
 
IOVA Iovance Biotherapeutics, Inc.
11.19
+7.18%
 
RARE Ultragenyx Pharmaceutical Inc.
50.99
0.00%
 
ITCI Intra-Cellular Therapies, Inc.
86.54
+2.11%
 
DNLI Denali Therapeutics Inc.
27.05
+4.20%